Interstitial lung abnormalities (ILAs) are parenchymal lung changes found on high-resolution CT. In routine use of high-resolution CT, non-specific findings are frequently reported, which has prompted ...

A 79-year-old man with recurrent oropharyngeal cancer has developed the first documented case of severe drug-induced interstitial lung disease following photoimmunotherapy with cetuximab-sarotalocan ...

Results come after positive results from a trial among people with idiopathic pulmomary disease.

In this randomized controlled trial, treatment with nerandomilast led to slower declines in forced vital capacity (FVC) in patients with progressive pulmonary fibrosis over 52 weeks 2. The occurrence ...

The global progressive pulmonary fibrosis (PPF) treatment market is projected to be valued at USD 4,044.6 Million in 2025 and is expected to reach USD 8,182.4 Million by 2035, registering a CAGR of 7.

The FDA has approved Zegfrovy (sunvozertinib) for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell ...

FDA accelerates approval of sunvozertinib for advanced NSCLC with EGFR mutations, offering new hope for patients after ...

Researchers have successfully generated lung cells similar to alveolar epithelial type 2 (AT2) cells from mouse embryonic ...